Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 21:11:632256.
doi: 10.3389/fonc.2021.632256. eCollection 2021.

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Alfredo Tartarone  1 , Vittoria Lapadula  1 , Concetta Di Micco  2 , Gemma Rossi  3 , Carlotta Ottanelli  3 , Andrea Marini  3 , Roberta Giorgione  3 , Katia Ferrari  4 , Martina Catalano  3 , Luca Voltolini  5 , Enrico Mini  6 , Giandomenico Roviello  6
Affiliations
Review

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Alfredo Tartarone et al. Front Oncol. .

Abstract

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.

Keywords: MET; genetic testing; non small cell lung cancer; oncogenic drivers; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Novel druggable oncogenic drivers in NSCLC.
See this image and copyright information in PMC

References

    1. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. . Osimertinib in Untreated Egfr-Mutated Advanced non-Small-Cell Lung Cancer. N Engl J Med (2018) 378:113–25. 10.1056/NEJMoa1713137 - DOI - PubMed
    1. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. . Updated Overall Survival and Final Progression-Free Survival Data for Patients With Treatment-Naive Advanced ALK-positive non-Small-Cell Lung Cancer in the ALEX Study. Ann Oncol (2020) 31:1056–64. 10.1016/j.annonc.2020.04.478 - DOI - PubMed
    1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. . Metastatic non Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Updated Version 15 September 2020. Ann Oncol (2018) 29:iv192–237. 10.1093/annonc/mdy275 - DOI - PubMed
    1. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. . Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med (2018) 142:321–46. 10.5858/arpa.2017-0388-CP - DOI - PubMed
    1. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. . Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol (2018) 36:911–9. 10.1200/JCO.2017.76.7293 - DOI - PubMed